MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


AIM WINNERS & LOSERS: Aptamer says struggling to convert pipeline

ALN

The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Bushveld Minerals Ltd, up 20% at 4.35 pence, 12-month range 3.5p-10.6p. The South Africa-focused vanadium producer and energy storage solutions company enters into term sheet with Orion Mine Finance to refinance its existing convertible loan note. Will refinance around $45 million due in November into three components, including a $27 million three-year term loan, new CLN of $13.5 million maturing in 2028, and conversion of $4.5 million of existing CLN into shares at 6p each. ‘The proposed refinancing will resolve a large liability that became current in 2023 and will remove significant near-term pressure on the company’s balance sheet, in the process supporting sustainable growth and cash generation of our business,’ says Chief Executive Fortune Mojapelo.

----------

Sareum Holdings PLC, up 12% at 140.05p, 12-month range 55.1p-264p. The Cambridge-based biotechnology company developing kinase inhibitors for autoimmune disease and cancer wins approval to conduct phase 1 clinical studies on SDC-1801 in Australia. SDC-1801 is a TYK2/JAK1 inhibitor being investigated as a potential new therapeutic for autoimmune diseases, with a focus on psoriasis. Will work alongside specialist clinical units in Melbourne to begin a phase 1a trial as soon as possible.

----------

AIM - LOSERS

----------

Aptamer Group PLC, down 46% at 13.78p, 12-month range 13p-122.95p. The developer of novel Optimer binders for the life sciences industry updates on the financial year ending June 30. In the first 10 months, revenue was around £1.4 million, with its pipeline taking ‘longer than expected to convert’. The delays were especially apparent in licensing and royalty-based contracts. It now expects annual revenue to be ‘materially’ below the previous year’s level of £4.0 million. It reports a ‘healthy’ pipeline across fee-for-service and licensing, with some of the revenue to fall in the current year, but most - ‘if converted’ - in the next year. With cash running low at £700,000 at the end of April, the firm is mulling a range of funding options, which could be non-dilutive or dilutive in nature.

----------

Copyright 2023 Alliance News Ltd. All Rights Reserved.